Inovio's dBITE shows tumor-killing activity in peer-reviewed publication
Inovio's novel DNA-encoded Bi-specific T Cell Engagers, or dBiTEs, generated potent anti-tumor activities and cleared established tumors in preclinical studies according to results published in peer-reviewed journal JCI Insight article by Inovio and its collaborators at The Wistar Institute. For this study, Inovio developed a novel dBiTE for the treatment of ovarian and breast cancers. A single dose of Inovio's HER2 dBiTE resulted in high levels of corresponding BiTE in mice for up to four months, exceeding what is typically displayed with the currently approved BiTE's short half-life of only a few hours. The HER2 dBiTE treatment effectively killed HER2-expressing tumor cells resulting in a near-complete tumor clearance. Inovio's CEO Joseph Kim said, "(...) Our dBiTE technology could be utilized to overcome the greatest shortcomings of traditional BiTEs, particularly its incredibly short half-life. Based on these promising preclinical results, we plan to rapidly advance our first dBiTE candidate into clinical testing, as well as develop more cancer tumor-targeting dBiTEs as partnering candidates." Inovio's dBiTE is a new application of Inovio's dMAb platform.